Summary We describe two Li-Fraumeni syndrome families. Family A was remarkable for two early childhood cases of adrenocortical tumours, family B for a high incidence of many characteristic cancers, including a childhood case of choroid plexus tumour. Using direct sequencing, we analysed exons 5-9 of the p53 gene in constitutional DNA of individuals from both families and found two novel germline mutations in exon 5. In family A, we detected a point substitution in codon 138 (GCC to CCC), which resulted in the replacement of the alanine by a proline residue. Family B harboured a single-base pair deletion in codon 178 (CAC to -AC), resulting in a frameshift and premature chain termination. Three out of six tumours examined from both families, a renal cell carcinoma, a rhabdomyosarcoma and a breast cancer, showed loss of heterozygosity and contained only the mutant p53 allele. The remaining three neoplasms, both adrenocortical tumours and the choroid plexus tumour retained heterozygosity. Immunohistochemistry with anti-p53 antibody confirmed accumulation of p53 protein in tumours with loss of heterozygosity, while the remaining tumours were p53 negative. These results support the view that complete loss of activity of the wild-type p53 need not be the initial event in the formation of all tumours in Li-Fraumeni individuals.
The Li-Fraumeni syndrome (LFS), first described in 1969 (Li and Fraumeni, 1969) , is a rare dominantly inherited condition that confers an increased susceptibility to cancer to family members. These individuals are at a high risk of developing a large spectrum of cancers, often with a very early onset. Multiple primary tumours are also common. The prevalent types of cancer are soft-tissue sarcomas, osteosarcomas, brain tumours, leukaemias, adrenocortical carcinomas and premenopausal breast cancer, but other cancers have also been reported (Li et al, 1988) . A family with a high incidence of cancer is diagnosed as LFS if there is a proband with a sarcoma under 45 years, one first-degree relative with cancer under 45 years and another first-or second-degree relative with cancer under 45 years or a sarcoma at any age (Li et al, 1988) .
In 1990, germline mutations in the p53 tumour-suppressor gene, which is located on chromosome 17pl 3, were identified as a genetic basis of LFS (Malkin et al, 1990; Srivastava et al, 1990 ). Since then, a variety of germline mutations have been identified in approximately 50% of LFS families analysed (Birch et al, 1994a; reviewed in Malkin, 1994; Eeles, 1995; Frebourg et al, 1995) . In addition, germline p53 mutations have been reported in settings not conforming to the criteria of classical LFS, for example as in isolated sarcoma patients (Toguchida et al, 1992) or in individuals with multiple tumours (Malkin et al, 1992) . Similar to somatic p53 mutations frequently found in sporadic tumours, most of the germline mutations are missense mutations, clustering in several conserved domains of the p53 gene (Malkin, 1994; Eeles, 1995) .
At present it is not clear whether there is a heterogeneity in LFS with respect to presence or absence of germline p53 mutations (Wang et al, 1996) . There are cases of LFS pedigrees, however, in which the linkage between the cancer susceptibility and the p53 locus has been excluded (Birch et al, 1994b ).
In accordance with the concept of p53 being a tumoursuppressor gene, the tumours in LFS patients are expected to lose the functional (by the germline mutation unaffected) p53 allele.
There are several single-case reports and one recent larger study indicating, however, that loss of heterozygosity is not observed in a significant fraction of these tumours (Varley et al, 1997) .
Although genetic diagnosis of germline p53 mutations is possible in many LFS families, the syndrome is associated with medical, counselling, psychological and ethical problems . Up to now, no correlation between the type and location of the germline mutation within the p53 gene and clinical features has been identified. The exact penetrance and age-, sex-and sitespecific cancer risk figures for carriers of diverse mutations are not known. The heterogeneity of the malignancies does not allow a simple and effective preventive screening, and the treatment of aggressive tumours associated with LFS is often complicated. Further studies are therefore needed to generate additional background knowledge for pilot intervention efforts in carriers of germline p53 mutations.
To obtain further data on the nature and implications of specific p53 germline mutations and on the behaviour of the p53 gene and 
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PCR
Genomic DNA was isolated from peripheral blood lymphocytes using standard methods (Baas et al, 1984) . Exons 5 and 6 of the p53 gene were amplified by primers e56F (TGCCCTGACTT''7CAAC-TCTGTC) and e56B (CCACTGACAACCACCCTTAACC), exon 7
by primers e7F (AAGGCGCACTGGCCTCATCTTG) and e7B (CCAGTGTGCAGGGTGGCAAGTG) and exons 8 and 9 by primers e89F (GACCTGAT'I'CCTTACTGCCTC) and e89B (CCACTTGATAAGAGGTCCCAAG (Banerjee et al, 1995) . Shorter PCR products spanning the mutation sites were amplified using primers e56F and c138B (TGCTGTGACTGCTTGTAGATGG) in samples from family A and e56F and e5B (TCAGTGAGGAATCAGAGGCCTG) in samples from family B. In these cases, the number of PCR cycles was increased to 45.
Sequencing
The PCR products were purified from agarose gels using QIAquick Gel Extraction Kit (QIAGEN). Cycle-sequencing of both strands (Carothers et al, 1989) was performed using either of the two primers used in PCR with dye terminator chemistry and AmpliTaq FS (Perkin-Elmer). The products were analysed on an ABI 373A sequencer.
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RESULTS

Identification of germline mutations
The pedigrees of families A and B showed clustering of cancer cases, with a high proportion of tumours being characteristic for LFS and often occurring at a young age (Figure 1 ). Both families conformed to the criteria of classical LFS (Li et al, 1988) . Peripheral blood lymphocyte DNA samples from individuals A-III.2, A-IV. 1, A-IV.2 and B-III.2 were available. The results of the search for germline p53 mutations in these samples are summarized in Table 1 . In family A, the direct sequencing of PCR products generated from exons 5-9 of the p53 gene from lymphocyte DNA of individuals A-III.2, A-IV. 1 and A-IV.2 revealed heterozygosity for a G to C transversion in the first position of codon 138. The codon change from GCC to CCC resulted in an amino acid change from alanine to proline (Figure 2) .
The sequence analysis of constitutional DNA of individual B-III.2, the only living affected member of family B, revealed heterozygous deletion of one C nucleotide in the first position of codon 178 of the p53 gene. The frameshift caused by this deletion results, if translated, in the incorporation of 68 illegitimate amino acid residues and premature chain termination (Figure 2 ).
Analysis of tumours
Archival tumour samples from the renal cell carcinoma of A-II. 1, adrenocortical tumours of A-IV. 1 and A-IV.2, rhabdomyosarcoma of A-IV. 1, breast cancer of B-III.2 and brain tumour of B-IV. 1 were available for independent confirmation of the diagnoses as well as for DNA analysis and immunohistochemistry. The results of these studies are summarized in (1984) and van Slooten et al (1985) . The tumour retained heterozygosity in codon 138 of the p53 gene and p53 staining was negative.
The soft-tissue tumour of the above patient was a predominantly spindle-cell sarcoma with occasional tadpole and round rhabdomyoblasts positive for desmin, sarcomeric actin and myoglobin. It was classified as an embryonal rhabdomyosarcoma. It showed loss of the wild-type allele in codon 138 ( Figure 2 ) and strong nuclear staining with the anti-p53 antibody ( Figure 3B ).
The adrenocortical tumour of patient A-IV.2 was encapsulated, measuring 50x5Ox40 mm. Light microscopy revealed solid trabecular and solid alveolar pattems. The tumour cells showed moderate nuclear atypia. The mitotic count was low (<1/10 HPF).
No capsular or vascular invasion was found. The tumour was hormonally active with virilizing effects and was classified as an adrenocortical adenoma. This tumour did not show loss of heterozygosity in codon 138. It was generally p53 negative, although rare scattered foci of tumour cells with positive nuclear p53 staining were observed ( Figure 3C ).
The breast cancer of the patient B-III.2 from family B was classified as ductal infiltrating carcinoma. It showed loss of heterozygosity in codon 178 of the p53 gene and displayed only the mutant allele (Figure 2 ). The p53 immunohistochemistry revealed a strong staining of most tumour cells ( Figure 3D ). Non-neoplastic epithelial cells of breast ducts and lobules as well as stromal cells were negative.
The choroid plexus carcinoma of patient B-IV. 1 was characterized by marked cellular atypias with foci of solid growth pattern besides more typical papillary areas. The tumour DNA retained (Li et al, 1988) . Our analysis identified germline mutations in the p53 gene in both families studied. Family A is remarkable because of the occurrence of two cases of early childhood adrenocortical tumours in two sisters (A-IV.1 and A-IV.2) and a childhood sarcoma in the first child. The renal cell carcinoma of the grandfather of the two children (A-II. 1) is a rare, but already reported cancer in LFS (Li et al, 1988) . The presence of rhabdomyosarcoma and adrenocortical tumours in young children point to a high risk of carrying a germline p53 mutation (Birch et al, 1994a) . Indeed, a germline mutation in codon 138 was identified in both girls and their mother (A-III.2). The mother is now 30 and cancer free, but is at a very high risk of developing breast cancer. The outbreak of early childhood cancer in children from a 30-year-old asymptomatic carrier whose ancestors developed cancer between 37 and 45 years of age may possibly have been influenced in the last generation by a change in the genetic background on which the germline p53 mutation exists in this pedigree.
The functional consequences of the missense mutation in codon 138 remain to be determined, but several lines of evidence support its causal role in the LFS in family A. Codon 138 is located in the DNA binding domain of the p53 protein (Cho et al, 1994) . The alanine residue in position 138 is located in the conserved domain II. of p53 and shows absolute evolutionary conservation in p53 sequences of all vertebrate and one mollusc species reported so far (Soussi and May, 1996) . Owing to the cyclic nature of proline, the replacement of alanine by proline may have profound consequences on the protein structure. No polymorphisms have been described for codon 138 (De Vries et al, 1996) . A different germline mutation of this codon, GCC to TCC, replacing alanine by serine, was described in a family with gliosarcoma and nonHodgkin's lymphoma (Kyritsis et al, 1994) . The databases of somatic p53 mutations in tumours list 13 tumours with missense codon 138 mutations, five of which are identical with the mutation seen in family A (De Vries et al, 1996; Hollstein et al, 1996) . In family A itself, the mutation segregates with cancer susceptibility, and two tumours analysed show loss of the wild-type allele while retaining the mutant allele.
Family B represents a textbook example of LFS. The occurrence of choroid plexus tumour in B-IV.1 supports the view that this tumour may also be frequent in LFS (Li and Fraumeni, 1994) .
The frameshift germline p53 mutation identified in this family very likely abolishes the function of the mutant allele. The deletion in codon 178 occurs in a contiguous stretch of five C nucleotides, which represents one of the hot spots for somatic insertiondeletion mutations in p53 . An identical mutation also plays a role in sporadic cancer and was reported as a British Journal of Cancer (1998) 77(7) somatic mutation in ten different tumours (De Vries et al, 1996; Hollstein et al, 1996) . Translation of the mutant allele can give rise to a truncated protein. There are several reports showing that mRNA corresponding to p53 alleles with premature stop codons is absent from cells harbouring these mutations in a heterozygous state (Felix et al, 1993; Horio et al, 1994 : Stolzenberg et al, 1994 .
Frameshift mutations caused by insertion-deletion events or splicing mutations represent approximately only 10% of germline p53 mutations reported so far (Malkin, 1994; Eeles, 1995) .
Individuals or families carrying these mutations do not show any particular features compared with those harbouring diverse missense mutations. Although it is tempting to speculate that the mutation in family B has a very high penetrance and that the cancer onset is relatively early, more data are needed to establish possible genotype-phenotype correlations in LFS.
Our studies of patterns of loss of heterozygosity at the p53 locus and of protein p53 accumulation yielded interesting results. Two out of four tumours analysed in family A and one of two in family B showed loss of the wild-type p53 allele at the site of the germline mutation, while the remaining tumours retained heterozygosity. This pattern is in agreement with published data, in which the fraction of tumours with loss of heterozygosity ranges from 44% to 69% (Varley et al, 1997) . Our results are further supported by immunohistochemistry with the anti-p53 antibody, which indicated the accumulation of the p53 protein in tumours that have lost the wild-type allele. With the exception of rare foci of p53-positive cells in the adrenocortical tumour of A-IV.2, no accumulation of p53 was detected in tumours that retained heterozygosity at the site of germline mutation. Although a second independent somatic mutation disabling the wild-type p53 allele in these tumours cannot be ruled out, the above results suggest that wild-type p53 is not inactivated here.
It is interesting that the tumour types in which neither loss of heterozygosity nor positive p53 staining were observed belong to early childhood tumours characteristic of LFS. While the sporadic adrenocortical tumours are most common between the fifth and seventh decade of life, a substantial fraction of childhood cases of this tumour belong to LFS families. Similarly, choroid plexus tumour may be another specific early manifestation of LFS. It may be possible that the initial event in the formation of these tumours in LFS individuals is not the complete loss of activity of the wildtype p53, but that they may be initiated in heterozygous cells by a p53 dosage effect during a period that is critical for the particular tissue or cell type. The post-natal regression of the fetal adrenal cortex and a progressive remodelling of the fetal zone into the definitive zonae fasciculata and reticularis (Symington, 1982) may be one such critical point.
The identification of germline p53 mutations is at present accompanied by counselling and medical problems ). The situation is slightly different for those members of cancer-prone families who are already affected by cancer (A-IV. 1, A-IV.2, B-III.2) or who are aware of their obligate carriership (A-II.2). The detection of germline p53 mutations in these individuals should lead to an offer for preventive screening measures and should be taken into account when selecting therapeutic strategies. The screening and therapeutic approaches should reflect the possible susceptibility to secondary iatrogenic cancers in LFS individuals and a limited response of tumours harbouring p53 mutations to certain agents. In light of current limited possibilities of effective preventive screening and effective therapy of tumours associated with LFS, however, any presymptomatic diagnosis in individuals at 50% risk (A-ILI.3, A-III.4) should be preceded by exhaustive and individual counselling. Testing of children (B-IV.2) represents a particular problem .
In summary, the two LFS families with two novel germline p53
mutations showing specific patterns of loss of heterozygosity at the p53 locus and of p53 accumulation in tumours add to the currently still expanding body of knowledge of this syndrome. Studies of LFS contribute to the general understanding of the processes of carcinogenesis. A better understanding of correlations between genotype and phenotype in LFS will eventually lead to the better management strategies that are needed for this rare but devastating disorder.
